Patients with vs without RA have a higher risk for avoidable hospitalizations for ambulatory care sensitive conditions, particularly heart failure and pulmonary edema.

Among patients with acute LBP, use of nonpharmacologic therapy was associated with reduced risk for overdose-related hospitalizations.

Metformin and SGLT2 inhibitors are associated with similar rates of incident gout among patients with type 2 diabetes.

For mothers with opioid use disorder (OUD), treatment with buprenorphine in pregnancy is associated with improved maternal and infant outcomes.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Patients with at least 5 comorbidities had worsened pain and functional scores compared with patients with 3 comorbidities at 12 months following TKA.

Urinary incontinence is not associated with moderate-to-vigorous physical activity (MVPA) classification, but is associated with cardiovascular disease (CVD) risk factors and comorbidity.

Despite widespread vaccine availability and improved treatment strategies, certain patients with SARDs remain highly vulnerable to severe COVID-19 outcomes.

Ultrasound-guided minimally invasive tenosynovial biopsy is a feasible, safe, and well-tolerated technique among patients with different stages of RA.

Changes in PROs can predict disease flares among patients with RA who discontinued csDMARD therapy after achieving sustained remission.

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...